Advertisement

Topics

Partnership extended to develop novel anti-cancer drugs targeting MCL1

08:26 EDT 14 Mar 2018 | EPM Magazine

Boehringer Ingelheim and Vanderbilt University have expanded their partnership to develop novel anti-cancer drugs that inhibit the myeloid cell leukaemia 1 (MCL1) protein, which is highly prevalent in many difficult to treat cancers.

Original Article: Partnership extended to develop novel anti-cancer drugs targeting MCL1

NEXT ARTICLE

More From BioPortfolio on "Partnership extended to develop novel anti-cancer drugs targeting MCL1"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...